DocGo Inc.
DCGO Nasdaq· Services-Health Services
Last close · Oct 27, 2026
$0.27
KIRA · Stoqly’s AI analyst, in plain words
- DocGo Inc. had $322M of revenue in fiscal 2025, down 47.7% on the year before. Over five years, revenue changed +27.9% a year on average.
- Its operating margin was −55.3%, down 59.9 pts: of every 100 in sales, about −55 is left after running the business.
- DocGo Inc. lost $182M in fiscal 2025.
- Free cash flow was $29.9M in fiscal 2025, 9.3% of revenue.
- DocGo Inc. returned $10.8M to shareholders in fiscal 2025, 36% of free cash flow. The diluted share count fell 9.5%.
- DocGo Inc. has $34.1M more cash than debt.
Market cap
$26.7M
P/E
—
Revenue
$322M
Net income
−$182M
Free cash flow
$29.9M
Operating margin
−55.3%
DocGo Inc. in 30 seconds · fiscal 2025
Are sales growing?
−47.7%
No. Sales fell 47.7% last year.
Does it make a profit?
−56.6%
No. It lost money last year.
Does profit turn into cash?
9.3%
Partly. 9.3% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What DocGo Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- DocGo Inc.
- CIK
- 0001822359
DocGo Inc. · DCGO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $319M | $441M | $624M | $617M | $322M |
| Revenue growth | 238.7% | 38.2% | 41.7% | −1.2% | −47.7% |
| Net interest income | −$0.8M | $0.8M | $1.7M | — | — |
| Gross margin | −41.7% | −18.9% | — | — | — |
| Operating margin | 4.8% | 5.0% | 2.4% | 4.7% | −55.3% |
| Net income | $23.7M | $34.6M | $6.9M | $20.0M | −$182M |
| Net margin | 7.4% | 7.9% | 1.1% | 3.2% | −56.6% |
| Diluted EPS | $0.25 | $0.34 | $0.06 | $0.18 | −$1.84 |
| Cash | |||||
| Cash from operations | −$1.9M | $28.9M | −$64.5M | $70.1M | $34.5M |
| Capital expenditure | $4.8M | $3.2M | $7.3M | $3.6M | $4.5M |
| Free cash flow | −$6.8M | $25.7M | −$71.8M | $66.5M | $29.9M |
| FCF margin | −2.1% | 5.8% | −11.5% | 10.8% | 9.3% |
| Share buybacks | $0.0M | $3.7M | $0.0M | $13.8M | $10.8M |
| Share count change | 62.5% | 8.6% | 2.6% | 3.6% | −9.5% |
| Debt and strength | |||||
| Cash and short-term investments | $176M | $157M | $59.3M | $89.2M | $51.0M |
| Debt incl. finance leases | $10.7M | $9.3M | $11.5M | $14.7M | $17.0M |
| Shareholders' equity | $220M | $273M | $301M | $321M | $144M |
| Net debt / EBITDA | −9.3x | −4.6x | −1.5x | −1.7x | — |
| Current ratio | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Interest coverage | 250.5x | 966.0x | — | — | — |
| Returns and quality | |||||
| Return on capital | 33.3% | 18.7% | 4.1% | 8.0% | −150.9% |
| Return on equity | 17.3% | 14.0% | 2.4% | 6.4% | −78.5% |
| Return on tangible equity | 11.9% | 16.4% | 3.2% | 8.1% | −126.7% |
| Piotroski F-score | 4 | 6 | 3 | 7 | 4 |
| Altman Z'' | 6.7 | 5.5 | 4.0 | 5.4 | −4.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
DocGo Inc. · DCGO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.27 a share, the company is worth $26.7M.
Source: SEC EDGAR XBRL filings (CIK 0001822359). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.